TWST posts record $118.4M Q3 FY2026 revenue, raising guidance
Twist Bioscience reported record $118.4 million Q3 FY26 revenue, growing 23% sequentially for the 14th consecutive time. The company raised FY26 revenue guidance and reiterated adjusted EBITDA breakeven expectations.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day